Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab DOI Creative Commons
Sandra Vukusic, Riley Bove, Ruth Dobson

et al.

Neurology Neuroimmunology & Neuroinflammation, Journal Year: 2024, Volume and Issue: 12(1)

Published: Dec. 17, 2024

Ocrelizumab labeling advises contraception for women during treatment and 6-12 months thereafter. Because pregnancies may occur this time, it is critical to understand pregnancy infant outcomes in with multiple sclerosis (MS) after ocrelizumab exposure.

Language: Английский

Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab DOI Creative Commons
Sandra Vukusic, Riley Bove, Ruth Dobson

et al.

Neurology Neuroimmunology & Neuroinflammation, Journal Year: 2024, Volume and Issue: 12(1)

Published: Dec. 17, 2024

Ocrelizumab labeling advises contraception for women during treatment and 6-12 months thereafter. Because pregnancies may occur this time, it is critical to understand pregnancy infant outcomes in with multiple sclerosis (MS) after ocrelizumab exposure.

Language: Английский

Citations

1